Now I have enough data. Let me compile the comprehensive answer for all 10 questions.---
Internal Assessment Theory Examination - Paper I
Gynecologic Oncology - Model Answers
Q1a. Principles of Management of Cervical Carcinoma in Pregnancy [6]
General Principles
DIAGNOSIS CONFIRMED IN PREGNANCY
│
▼
Multidisciplinary Team
(Gyn Oncologist + MFM + Radiation
Oncologist + Neonatologist)
│
▼
Individualize based on:
• Stage of disease
• Gestational age
• Desire to continue pregnancy
• Fetal viability
| Principle | Key Points |
|---|
| Staging | MRI preferred (no radiation); PET-FDG avoided; CT with shielding if needed |
| Biopsy | Punch biopsy safe in all trimesters; conization if microinvasion suspected (best in 2nd trimester) |
| Treatment delay | Acceptable for Stage I-II: up to 32 weeks with close monitoring; no delay for Stage III-IV |
| Delivery mode | Classical caesarean section preferred if definitive surgery planned |
| Timing | Deliver at fetal maturity (34-36 wks), then definitive treatment |
| NACT | Neoadjuvant chemo (platinum-based) used from 14 weeks if delay needed; preserves pregnancy while controlling disease |
Stage-Based Management
| Stage | Gestational Age | Management |
|---|
| IA1 (no LVSI) | Any | Conization; definitive Rx postpartum |
| IA1 (LVSI+)/IA2 | <22 wks | Delay + close follow-up or NACT |
| IA1/IA2 | >34 wks | Deliver, then treat |
| IB1-IIA | <22 wks | Individualize; NACT or delivery if mature |
| IB1-IIA | >22 wks | Consider delay to 34 wks then deliver |
| IB2/II-IV | <22 wks | Treatment in pregnancy (NACT, RT) |
| IB2/II-IV | >22 wks | Possible short delay to fetal viability |
Q1b. Management: 36-year-old, Nulliparous, 24 wks Pregnant, Stage IIIC1(r), Neuroendocrine Cervical Cancer [4]
Clinical Problem: Advanced stage + rare aggressive histology + desire likely for pregnancy/fertility + 24 weeks gestation
Decision Flowchart
Stage IIIC1(r) Neuroendocrine Ca Cx
at 24 weeks gestation
│
▼
Counsel: Poor prognosis
- Neuroendocrine Ca = highly aggressive
- Stage IIIC1r = nodal mets on imaging
- 24 weeks = fetus NOT viable yet
│
▼
MDT Discussion + Informed Consent
│
─────────────────────
│ │
▼ ▼
Patient chooses Patient desires
treatment now to delay
│ │
▼ ▼
Terminate NACT from 14 wks:
pregnancy Cisplatin + Etoposide
then proceed (Preferred for NECC)
to CCRT ± close monitoring
│
▼
Aim for viability
(28-32 wks)
Classical CS
│
▼
Definitive CCRT
post-delivery
Key Points for NECC specifically:
- NECC = Small cell/large cell neuroendocrine; behaves like SCLC
- Preferred chemotherapy: Cisplatin + Etoposide (PE regimen) - not standard squamous/adeno regimens
- Platinum-based NACT is acceptable after 14 weeks (organogenesis complete)
- Radiation is contraindicated during pregnancy
- Prognosis is poor regardless - frank counseling mandatory
- Consider offering termination with immediate definitive chemoradiotherapy as this offers best oncologic outcome
- After delivery: CCRT (Cisplatin weekly × 5 + EBRT + brachytherapy) as definitive treatment
Q2a. Signal Transduction Pathways [6]
Major Pathways
| Pathway | Receptor/Trigger | Key Mediators | End Effect |
|---|
| RAS-MAPK | RTK (EGFR, HER2) | RAS→RAF→MEK→ERK | Proliferation, differentiation |
| PI3K-AKT-mTOR | RTK, GPCR | PI3K→PIP3→AKT→mTOR | Survival, growth, angiogenesis |
| JAK-STAT | Cytokine receptors | JAK→STAT3/5 | Proliferation, immune evasion |
| WNT-β-catenin | Frizzled receptor | β-catenin→TCF/LEF | Stem cell renewal, EMT |
| Hedgehog (Hh) | Patched → Smoothened | GLI transcription factors | Embryogenesis, tumor growth |
| NOTCH | Delta/Jagged ligands | Presenilin→NICD | Stem cells, angiogenesis |
| TGF-β/SMAD | TGF-β receptor | SMAD2/3→nucleus | Early suppressor → late promoter |
| NF-κB | TNF, IL-1, stress | IKK→NF-κB→nucleus | Inflammation, anti-apoptosis |
EXTRACELLULAR SIGNAL (Growth factor, ligand)
│
▼
Receptor (RTK / GPCR / Nuclear)
│
─────────────────────
│ │
▼ ▼
RAS-MAPK PI3K-AKT
pathway pathway
│ │
▼ ▼
ERK1/2 AKT → mTOR
│ │
└────────┬──────────┘
▼
NUCLEUS: Transcription Factors
(MYC, FOS, JUN, FOXO, HIF-1α)
│
▼
Cell Proliferation / Survival
Angiogenesis / Invasion / Metastasis
Q2b. Role in Chemotherapeutics of Gynecological Cancers [4]
| Pathway | Targetable Agent | Cancer |
|---|
| HER2/EGFR | Trastuzumab, Pertuzumab | Endometrial, Cervical |
| PI3K-AKT-mTOR | Everolimus, Temsirolimus, Alpelisib | Endometrial (PIK3CA mut), Ovarian |
| VEGF-angiogenesis | Bevacizumab, Pazopanib | Ovarian, Cervical |
| PARP (via HR pathway) | Olaparib, Niraparib, Rucaparib | Ovarian (BRCA1/2 mut) |
| PD-1/PD-L1 (immune) | Pembrolizumab, Dostarlimab | Endometrial (MMR-d), Cervical |
| FGFR | Erdafitinib | Endometrial (FGFR2 mut) |
| MEK | Trametinib | Low-grade serous ovarian |
| CDK4/6 | Ribociclib | Endometrial |
Key mechanism: Targeted agents block specific pathway nodes → halt proliferation/induce apoptosis without systemic cytotoxicity of conventional chemo.
Q3. 60-year-old lady with Ascites + Bilateral Adnexal Masses [4+4+2]
Differential Diagnosis [4]
| Category | Diagnosis | Distinguishing Features |
|---|
| Primary Ovarian | High-grade serous carcinoma (MOST COMMON) | Bilateral, Ca-125 ↑↑, BRCA |
| Endometrioid carcinoma | Often unilateral, endometriosis |
| Mucinous carcinoma | Usually unilateral, large |
| Clear cell carcinoma | Younger women, unilateral |
| Low-grade serous | Slower growing, bilateral |
| Primary Peritoneal | PPSC | Normal/small ovaries, diffuse peritoneal disease |
| Fallopian tube Ca | FTCA | Colicky pain, hydrops tubae profluens |
| Metastatic | Krukenberg tumor (stomach/colon primary) | Bilateral, solid, mucin-secreting cells |
| Breast metastasis | History of breast Ca |
| Colon/appendix (LAMN) | Mucin, pseudomyxoma peritonei |
| Lymphoma | Systemic symptoms, LAP |
| Benign (less likely) | Bilateral benign ovarian cysts | Ascites rare |
IHC Panel to Determine Origin [4]
| IHC Marker | Positive In | Negative In |
|---|
| PAX8 | Ovarian/tubal/endometrial | GI, breast |
| WT1 | High-grade serous (ovarian/tubal/peritoneal) | Endometrioid, mucinous, metastatic |
| CK7 | Ovarian, endometrial, breast | Colorectal (usually CK7-) |
| CK20 | Colorectal, mucinous ovarian | HGSC |
| CDX2 | GI primary (Krukenberg) | Ovarian primary |
| SATB2 | Lower GI tract metastasis | Ovarian primary |
| ER/PR | Endometrioid, low-grade serous, breast | HGSC (usually ER-) |
| HER2 | Breast, some endometrial | Most ovarian |
| GCDFP-15 | Breast primary | Ovarian |
| CA-125 | HGSC (not specific) | - |
| p53 aberrant | HGSC (mutation pattern) | Other |
| p16 block+ | HGSC | - |
Algorithm:
Bilateral adnexal mass + ascites
│
▼
CK7+ / CK20- → Ovarian/endometrial primary
WT1+ / PAX8+ → HGSC likely
CDX2+ / CK20+ → GI metastasis (Krukenberg)
GCDFP-15+ → Breast metastasis
Factors Determining Primary Surgery in Ovarian Cancer [4]
| Factor | Favors PDS | Favors NACT-IDS |
|---|
| Performance status | ECOG 0-1 | ECOG 2+ |
| Surgical resectability | Resectable (CT/lap score) | Non-resectable (diffuse SB mesentery, porta hepatis, multiple SB segments) |
| Disease extent | Stage IIIB-C (limited peritoneal) | Stage IV (pleural effusion, parenchymal liver mets, inguinal nodes) |
| Nutritional status | Albumin >3.5 | Albumin <3.5, severe malnutrition |
| Comorbidities | None/controlled | Significant cardiac/renal/pulmonary |
| Laparoscopy score | Fagotti score ≤8 | Fagotti score >8 |
| Predicted R0 | Achievable | Not achievable |
| CA-125/CEA ratio | >25 (suggests primary) | - |
Key principle (2024 evidence): Goal is R0 resection. PDS preferred if R0 achievable. NACT-IDS is NOT inferior to PDS when R0 is unlikely at primary surgery (CHORUS, EORTC 55971 trials).
Counseling [2]
- Explain likely diagnosis of advanced ovarian cancer (Stage III-IV)
- Discuss need for tissue diagnosis (ascites tapping/laparoscopy)
- Two treatment paths: Primary debulking vs NACT × 3-4 cycles then interval surgery
- Surgery involves bowel resection, splenectomy, peritonectomy - risk of colostomy
- Chemotherapy: Carboplatin + Paclitaxel ± Bevacizumab (frontline)
- PARP inhibitor maintenance if BRCA1/2 mut / HRD positive
- 5-year survival Stage III ~40-50%, Stage IV ~20-30%
- Discuss clinical trial enrollment where available
Q4. Anatomy and Management of Ureteric Injuries in Gynecologic Oncology [4+6]
Anatomy of Ureter Relevant to Gyn Oncology [4]
PELVIC COURSE OF URETER (Sites of Injury)
L4-L5 level: Crosses common iliac artery
[1st danger zone]
↓
Lateral pelvic wall: Courses in retroperitoneum
medial to ovarian vessels
[2nd danger zone - ovarian pedicle ligation]
↓
Passes under uterine artery
"Water under the bridge"
1.5-2 cm lateral to cervix
[3rd danger zone - MOST COMMON site]
↓
Passes through ureteric tunnel
(Cardinal/Mackenrodt ligament)
[4th danger zone - radical hysterectomy]
↓
Enters bladder trigone
| Site | Operation at Risk | Frequency |
|---|
| Pelvic brim (crossing iliac vessels) | Para-aortic lymphadenectomy, pelvic sidewall dissection | Uncommon |
| Ovarian fossa | Oophorectomy, adnexectomy | Common |
| Uterine artery crossing (1.5cm lateral to cervix) | Hysterectomy | Most common (~75%) |
| Ureteric tunnel | Radical hysterectomy (Wertheim) | Common in radical cases |
| Ureterovesical junction | Anterior exenteration, anterior colporrhaphy | Uncommon |
Types of Injury
| Type | Features |
|---|
| Crush/clamp | Ischemia, delayed necrosis, fistula |
| Ligation | Complete obstruction, silent hydroureter |
| Partial transection | Urinary leak, fistula |
| Complete transection | Immediate urinary extravasation |
| Devascularization | Delayed necrosis/fistula (most insidious) |
Management [6]
INTRAOPERATIVE RECOGNITION
│
├── Crush/Clamp only → Remove clamp immediately
│ Consider stenting
│
├── Ligation → Removal of ligature + assess viability
│ + stenting
│
├── Partial laceration (<50%) →
│ Primary repair over ureteric stent (spatulated)
│
└── Complete transaction →
┌─────────────────────────────────┐
│ Site determines repair type │
│ │
▼ ▼
Upper/mid ureter Distal ureter (<5cm from UVJ)
│ │
Ureteroureterostomy Ureteroneocystostomy
(spatulated end-end) (Boari flap if needed)
│ │
│ Psoas hitch if tension
▼ ▼
Stent × 4-6 weeks Stent × 4-6 weeks
Delayed Presentation
| Finding | Investigation | Management |
|---|
| Flank pain, fever, ileus | CTU, IVU | Nephrostomy (temporize) |
| Urinary fistula (ureterovaginal) | Dye test, cystoscopy, CTU | Conservative 4-6 weeks; surgical repair if no resolution |
| Hydroureteronephrosis | Ultrasound, CTU | Retrograde stenting or percutaneous nephrostomy |
Principles of Repair:
- Tension-free anastomosis
- Watertight closure
- Spatulated ends
- Stented drainage
- Retroperitoneal drain
- Correct underlying pathology
Prevention:
- Pre-op ureteric stenting (controversial but used in redo surgery/radiation fields)
- Early ureteric identification and dissection
- Adequate exposure
- Stay in avascular planes
Q5. Cancer Prehabilitation [2+8]
Definition [2]
Cancer Prehabilitation = A process on the continuum of care that occurs between cancer diagnosis and the beginning of acute treatment; includes physical and psychological assessments that establish a baseline functional level, identify impairments, and provide targeted interventions to improve a patient's health to reduce the incidence and severity of treatment-related side effects.
(Silver & Baima, 2013 - original definition)
Prehabilitation in Ovarian Cancer Awaiting Primary Cytoreductive Surgery [8]
Components (MULTIMODAL MODEL)
DIAGNOSIS OF ADVANCED OVARIAN CANCER
│
▼
┌─────────────────────────┐
│ BASELINE ASSESSMENT │
│ (Within 2 weeks) │
│ • Nutritional (SGA) │
│ • Functional (6MWT, │
│ hand grip strength) │
│ • Psychological (GAD7, │
│ PHQ-9) │
│ • Cardiopulmonary │
│ (CPET / VO2 max) │
└────────────┬────────────┘
│
▼
┌─────────────────────────┐
│ PREHAB PROGRAM │
│ (3-6 weeks before CRS) │
│ │
│ 1. Exercise │
│ 2. Nutrition │
│ 3. Psychosocial │
│ 4. Anemia correction │
│ 5. Medications review │
└────────────┬────────────┘
│
▼
PRIMARY CRS
(Optimal outcome)
1. Exercise Component
| Type | Details | Frequency |
|---|
| Aerobic | Walking, cycling (moderate intensity) | 150 min/week |
| Resistance | Major muscle groups, progressive | 2-3×/week |
| Flexibility | Yoga, stretching | Daily |
| Inspiratory muscle training | Incentive spirometry, threshold IMT | 30 min/day |
2. Nutritional Optimization
| Issue | Intervention |
|---|
| Malnutrition (common in advanced OC) | Dietitian review; high-protein diet (1.5 g/kg/day) |
| Ascites-related anorexia | Small frequent meals; ascites drainage |
| Sarcopenia | Whey protein supplementation, BCAA |
| Immunonutrition | Arginine, glutamine, omega-3 (perioperative) |
| Weight loss >10% | Consider enteral nutrition |
3. Psychosocial Support
- Anxiety/depression screening (PHQ-9, GAD7)
- Cognitive behavioral therapy
- Mindfulness-based stress reduction
- Peer support groups
- Explain surgery + expected recovery
4. Anemia Correction
| Hb Level | Intervention |
|---|
| Hb 8-10 g/dL | IV Iron (ferric carboxymaltose) ± EPO |
| Hb <8 g/dL | Blood transfusion pre-op |
| Iron deficiency | IV Iron 4-6 weeks before surgery |
5. Other
- Optimize diabetes, HTN, cardiac disease
- Prehabilitative smoking cessation (≥4 weeks)
- Bowel preparation counseling
- DVT prophylaxis discussion
- Stoma counseling if bowel resection anticipated
Evidence
| Trial/Review | Finding |
|---|
| Ribero et al. (IJGC 2026) | Fitness predictors + prehab algorithms in advanced OC - critical review supports multimodal prehab |
| Pegreffi et al. (Eur J Surg Oncol 2025) | Exercise in OC: calls for standardized RCTs; current evidence supports feasibility |
| ERAS in OC | Prehab integral to ERAS; reduces LOS, complications |
Q6. HPV Tests - Classification, Validation, and Screening Choice [2+4+4]
Classification of HPV Tests Available [2]
| Category | Test Type | Examples |
|---|
| Signal Amplification | Hybrid Capture 2 (HC2) | Qiagen HC2 (gold standard) |
| Target Amplification (PCR) | Real-time PCR | Cobas 4800 (Roche), Abbott RealTime |
| Transcription-Mediated Amplification | mRNA (E6/E7) detection | APTIMA HPV (Hologic) |
| In situ hybridization | CISH/FISH | Research/tissue based |
| Genotyping | Individual type ID | Linear Array, Onclarity, LIPA genotyping |
| Extended genotyping | Partial genotyping | Onclarity (HPV16/18/31/45/51/52/other) |
| POC tests | Rapid, near-patient | careHPV (Qiagen), GeneXpert |
| Self-sampling compatible | On vaginal self-swab | Cobas, Aptima validated for self-sample |
Principles of HPV Test Validation [4]
International Standards (Meijer Criteria / WHO 2021)
| Criterion | Requirement |
|---|
| Clinical sensitivity | ≥90% relative sensitivity vs. HC2 for CIN2+ |
| Clinical specificity | ≥98% relative specificity vs. HC2 for <CIN2 |
| Reproducibility (intra-lab) | Kappa ≥0.87 |
| Reproducibility (inter-lab) | Kappa ≥0.87 |
| Reference population | Validated in women ≥30 years |
| Study design | Paired samples, colposcopy as standard |
| Sample type | Validated for cervical and self-collected (separately) |
Validated Tests (WHO pre-qualified / Meijer criteria met)
| Test | Manufacturer | Target |
|---|
| Cobas 4800 | Roche | DNA (HPV16/18/other 12 HR) |
| Hybrid Capture 2 | Qiagen | DNA (pooled 13 HR types) |
| APTIMA HPV | Hologic | mRNA (E6/E7) |
| Abbott RealTime | Abbott | DNA (HPV16/18/other HR) |
| Onclarity | BD | DNA (extended genotyping) |
| careHPV | Qiagen | DNA (POC, LMICs) |
Choice of HPV Test for Screening [4]
| Factor | Preferred Test | Rationale |
|---|
| Primary screening (HIC) | Cobas/Aptima/Abbott | Validated, genotyping capability |
| LMIC / resource-limited | careHPV (POC) | No lab infrastructure needed |
| Colposcopy triage | APTIMA (mRNA) | Higher specificity, less over-referral |
| Self-sampling programs | Cobas / Aptima | Validated for self-collected vaginal swab |
| Genotyping needed | Onclarity / Cobas | HPV16/18 immediate referral; others triage by cytology |
| Surveillance post-treatment | Any validated DNA PCR | Sensitive detection of persistence |
Screening Algorithm using HPV Test (WHO 2021 / FIGO 2024)
HPV Primary Screening (Women ≥30 years)
│
─────────────────────
│ │
▼ ▼
HPV NEGATIVE HPV POSITIVE
│ │
Repeat Genotyping
5 years │
─────────────────
│ │
▼ ▼
HPV 16/18+ Other HR-HPV+
│ │
▼ ▼
Direct Cytology triage
Colposcopy │
─────────────
│ │
▼ ▼
Normal ASCUS+/LSIL+
│ │
Repeat Colposcopy
1 year
Q7. CALLA Trial + INTERLACE Trial + Standard of Care in LACC [8+2]
INTERLACE Trial [4 of 8]
| Parameter | Details |
|---|
| Full name | GCIG INTERLACE Phase III RCT |
| Published | Lancet, October 2024 (McCormack et al.) |
| Design | International, multicenter, randomized phase 3 |
| Population | LACC (Stage IB1 node+, IB2, IIA2, IIB-IVA) |
| Intervention | 6 weeks induction chemo (weekly Carboplatin AUC2 + Paclitaxel 80 mg/m²) THEN standard CCRT |
| Control | Standard CCRT alone (Cisplatin 40 mg/m² weekly × 5 + EBRT 45-50.4 Gy + brachytherapy to 70 Gy EQD2) |
| Primary endpoint | PFS and OS (ITT) |
| Median follow-up | 67 months |
Key Results
| Outcome | Induction + CCRT | CCRT Alone | HR | P-value |
|---|
| 5-yr PFS | 72% | 64% | 0.65 | 0.013 |
| 5-yr OS | 80% | 72% | 0.60 | 0.015 |
| Grade ≥3 AE | 59% | 48% | - | - |
| Neutropenia | 19% | 5% | - | - |
Conclusion: First phase 3 trial to show significant survival benefit with induction chemo before CCRT. Considered a new standard of care for LACC.
CALLA Trial [4 of 8]
| Parameter | Details |
|---|
| Full name | CALLA - Durvalumab + CRT in LACC |
| Published | Lancet Oncology, December 2023 (Monk BJ et al.) |
| Design | Randomized, double-blind, phase 3 trial |
| Population | LACC (FIGO 2018 Stage IB2-IVA, node-negative and node-positive) |
| Intervention | Durvalumab (anti-PD-L1) concurrent with CCRT then durvalumab maintenance × 24 cycles |
| Control | Placebo + CCRT then placebo maintenance |
| Primary endpoint | PFS |
Key Results
| Outcome | Durvalumab | Placebo | HR | P-value |
|---|
| 2-yr PFS | 65.9% | 62.1% | 0.84 | 0.174 (NS) |
| OS | Not mature | - | - | NS |
Conclusion: CALLA trial was NEGATIVE - Durvalumab did not improve PFS or OS when added to CCRT.
Contrast with KEYNOTE-A18 (ENGOT-cx11)
| Parameter | Details |
|---|
| Drug | Pembrolizumab (anti-PD-1) |
| Published | Lancet 2024 (Lorusso et al.) |
| Result | POSITIVE - Significant OS benefit |
| Key difference from CALLA | Anti-PD-1 vs Anti-PD-L1; high-risk selection; different populations |
Standard of Care in LACC (2024-2025) [2]
LOCALLY ADVANCED CERVICAL CANCER (Stage IB2 - IVA)
│
▼
New Standard of Care (2025):
Induction Chemo × 6 weeks
(Carboplatin AUC2 + Paclitaxel 80 mg/m² weekly)
│
▼
Concurrent Chemoradiotherapy (CCRT)
Cisplatin 40 mg/m² weekly × 5
+ EBRT 45-50.4 Gy + Brachytherapy
(Total EQD2 ≥ 70 Gy to HR-CTV)
│
▼
± Pembrolizumab concurrent + maintenance
(in high-risk LACC - KEYNOTE-A18 data)
| Component | Regimen |
|---|
| Induction (INTERLACE) | Carbo AUC2 + Paclitaxel 80 × 6 weeks |
| Concurrent chemo | Cisplatin 40 mg/m² weekly × 5 |
| EBRT | 45-50.4 Gy in 25-28 fractions |
| Brachytherapy | HDR/PDR to total EQD2 ≥70 Gy (HR-CTV D90) |
| Immunotherapy (selected) | Pembrolizumab 200 mg q3w concurrent + maintenance × 2 years |
Q8. Chemotherapy for High-Risk/Recurrent GTN + Immunotherapy [8+2]
Chemotherapy in High-Risk and Recurrent GTN [8]
WHO Risk Score (Revised FIGO 2023)
| Score | 0 | 1 | 2 | 4 |
|---|
| Age | <40 | ≥40 | - | - |
| Antecedent | Mole | Abortion | Term preg | - |
| Interval (months) | <4 | 4-7 | 7-13 | >13 |
| Pre-Rx hCG | <10³ | 10³-10⁴ | 10⁴-10⁵ | >10⁵ |
| Tumor size (cm) | <3 | 3-5 | >5 | - |
| Metastatic site | Lung | Spleen/kidney | GI | Brain/liver |
| No. of mets | - | 1-4 | 5-8 | >8 |
| Prior chemo | - | Single drug | 2+ drugs | - |
Low risk: Score ≤6 → Single-agent chemo
High risk: Score ≥7 → Combination chemo (EMA-CO)
Treatment Algorithm
GTN DIAGNOSED (Post hCG monitoring / histology)
│
──────────────────────
│ │
▼ ▼
LOW RISK (≤6) HIGH RISK (≥7)
│ │
Single agent: First-line:
Methotrexate EMA-CO regimen
(MTX ± FA) │
OR 5-FU ▼
│ Complete response?
│ ─────────────────
│ │ │
▼ ▼ ▼
Response? YES NO (Resistant)
│ │ │
Yes → continue Monitor hCG Second-line:
No → EMA-CO (Remission) EMA-EP or BEP or
TP/TE or VIP
EMA-CO Regimen (First-line High-Risk)
| Drug | Day | Dose |
|---|
| Etoposide | 1,2 | 100 mg/m² IV |
| Methotrexate | 1 | 300 mg/m² 12-hr infusion |
| Actinomycin-D | 1,2 | 0.5 mg IV push |
| Folinic acid rescue | 2 (32-hr post MTX) | 15 mg q12h × 4 |
| Cyclophosphamide | 8 | 600 mg/m² |
| Vincristine (Oncovin) | 8 | 1 mg/m² (max 2 mg) |
| Cycle frequency | Every 14 days | - |
Remission rate: ~80-85% for high-risk GTN
Recurrent/Resistant GTN: Salvage Regimens
| Regimen | Drugs | Indication |
|---|
| EMA-EP | EMA + Etoposide + Cisplatin (replace CO) | EMA-CO failure |
| BEP | Bleomycin + Etoposide + Cisplatin | Refractory PSTT/ETT |
| TP/TE | Paclitaxel + Cisplatin or Etoposide | Platinum-sensitive |
| VIP | Vinblastine + Ifosfamide + Cisplatin | Multi-drug resistance |
| FAEV | Floxuridine + Actinomycin + Etoposide + Vincristine | Chinese center data |
| Surgery | Resection isolated mets | Single-site resistance |
| RT | Brain/liver mets (concurrent with chemo) | CNS mets |
Immunotherapy in GTN [2]
| Agent | Mechanism | Evidence |
|---|
| Pembrolizumab | Anti-PD-1 | Multiple case reports and series; CR in chemoresistant GTN; NivoMATCH trial data |
| Avelumab | Anti-PD-L1 | French case series; responses in refractory cases |
| Nivolumab | Anti-PD-1 | Case reports of CR |
| Ipilimumab (+ Nivo) | Anti-CTLA4 + PD-1 | Combination used in highly refractory cases |
Rationale: GTN expresses PD-L1 (especially choriocarcinoma); foreign paternal antigens create immunogenic microenvironment. PD-L1 overexpression correlates with immune evasion.
Current role: Reserved for chemo-resistant/refractory GTN. Pembrolizumab most evidence. Complete responses documented. No prospective RCT yet (case series + systematic reviews, Braga et al. 2023; Wang et al. 2023).
Caution: PSTT/ETT - less immunogenic, less responsive to immunotherapy.
Q9. Myocutaneous Flaps - Vascular Anatomy Classification + Vulvar Cancer [4+6]
Classification by Vascular Anatomy (Mathes & Nahai Classification) [4]
| Type | Vascular Pattern | Example Flaps | Feature |
|---|
| Type I | Single dominant pedicle | Tensor fasciae latae (TFL), Gastrocnemius | Simple, reliable |
| Type II | Dominant pedicle + minor pedicles | Gracilis, Biceps femoris, Trapezius | One pedicle sustains flap |
| Type III | Two dominant pedicles | Gluteus maximus, Rectus abdominis (bilateral), Serratus anterior | Can split on each pedicle |
| Type IV | Segmental pedicles | Sartorius, Tibialis anterior, External oblique | No single dominant; segmental |
| Type V | One dominant + secondary segmental | Latissimus dorsi, Pectoralis major, Internal oblique | Can be reversed |
Flaps Used in Vulvar Cancer Reconstruction [6]
| Flap | Type | Blood Supply | Defect Covered | Pros | Cons |
|---|
| Gracilis myocutaneous | Type II | Medial femoral circumflex + obturator artery | Vulva, perineum, vaginal reconstruction | Reliable, hidden donor site, well-vascularized | Small skin paddle, added morbidity |
| Vertical Rectus Abdominis (VRAM) | Type III | Deep inferior epigastric artery (DIEA) | Large vulvoperineal defects, exenteration reconstruction | Large skin paddle, reliable, fills dead space | Abdominal wall weakness, hernia risk |
| Tensor Fasciae Latae (TFL) | Type I | Lateral femoral circumflex artery | Inguinal, lateral vulvar defects | Simple arc of rotation | Limited reach to midline, contour deformity |
| Posterior Thigh (gluteal fold) | Type II | Descending branch of inferior gluteal artery | Posterior vulva, perineum | Excellent cosmesis, nearby | Limited bulk |
| Pudendal thigh flap (Singapore flap) | Fasciocutaneous | Internal pudendal artery | Perineum, posterior vaginal wall | Sensate, good cosmesis | Limited volume |
| Gluteus maximus | Type III | Superior/inferior gluteal arteries | Large perineal defects, post-exenteration | Bulky fill, reliable | Donor site morbidity, sitting discomfort |
| Lotus/Singapore flap | Fasciocutaneous | Internal pudendal artery | Vagina, vulva | Vulvar sensation preserved | Limited use if radiation damage |
Indications by Defect Size
VULVAR DEFECT AFTER RADICAL SURGERY
│
─────────────────────────────
│ │ │
▼ ▼ ▼
Small defect Medium defect Large/post-exenteration
(<4 cm) (4-8 cm) defect (>8cm)
│ │ │
Primary Gracilis OR VRAM flap OR
closure Pudendal Gracilis bilateral
thigh (SFF) OR Gluteus maximus
Acceptability in Vulvar Cancer:
- Allows radical excision with clear margins without primary closure tension
- Reduces wound dehiscence (common post-vulvectomy - up to 40-50%)
- Improves quality of life, body image, sexual function
- Essential after exenteration or bilateral inguinofemoral lymphadenectomy
- VRAM preferred for total vulvectomy + vaginectomy
- Gracilis flap preferred for neovagina + perineal reconstruction
Q10. Role of Minimally Invasive Surgery (MIS) in Gynecologic Oncology [10]
Overview
| Modality | Platforms |
|---|
| Laparoscopy | Conventional (2D), 3D laparoscopy |
| Robotic-Assisted | da Vinci Si/Xi, Hugo RAS, Versius |
| Single-port | LESS, r-LESS |
| Vaginally assisted | LAVH, VALRH |
Applications by Cancer Site
1. Endometrial Cancer
| Procedure | Evidence | Recommendation |
|---|
| Total laparoscopic hysterectomy + BSO + pelvic node assessment | LAP2 trial (GOG-LAP2): equivalent oncologic outcome, less complications | Standard of care (Grade A) |
| Sentinel lymph node biopsy (SLN) | FIRES trial: 97% sensitivity; reduces full lymphadenectomy | Recommended (NCCN/ESGO 2024) |
| Robotic surgery | Equivalent outcomes; better ergonomics; higher cost | Accepted alternative |
| Para-aortic staging | Technically feasible; robotic preferred | Selected cases |
2. Cervical Cancer - CRITICAL NOTE
| Aspect | Evidence | Recommendation |
|---|
| Radical hysterectomy (MIS) | LACC Trial 2018 (Ramirez et al.): MIS inferior to open (4-yr DFS 86% vs 96.5%; HR=6.0) | MIS radical hysterectomy NOT recommended for early cervical cancer |
| Sentinel LN biopsy | Acceptable; ongoing evaluation | Cautiously accepted |
| Staging procedures | MIS acceptable | Acceptable |
| Open radical hysterectomy | Standard of care | Recommended |
LACC Trial Impact: This landmark 2018 NEJM trial completely changed practice - open radical hysterectomy is now the standard for cervical cancer (FIGO IA2-IB1).
3. Ovarian Cancer
| Procedure | Evidence | Recommendation |
|---|
| Laparoscopic staging (early) | Equivalent; less morbidity | Acceptable for comprehensive staging Stage I-II |
| Laparoscopic assessment (resectability) | Fagotti scoring system | Recommended before deciding PDS vs NACT |
| CRS via MIS | Not recommended for advanced OC | Open approach for CRS |
| HIPEC + CRS | Open approach standard | MIS HIPEC experimental |
| Second-look laparoscopy | Largely abandoned | Historical |
4. Vulvar Cancer
| Procedure | Evidence | Recommendation |
|---|
| Sentinel LN biopsy (SLNB) | GROINSS-V trial: safe if T<4cm, unifocal, no suspicious nodes | Standard for eligible cases |
| Laparoscopic inguinal LN dissection | Limited data; feasibility shown | Investigational |
5. Staging Laparoscopy
Role of Diagnostic/Staging Laparoscopy:
├── Ovarian cancer: Fagotti score for PDS vs NACT decision
├── Cervical cancer: Para-aortic node sampling (stage IB2+)
├── Endometrial: Full staging (hysterectomy + BSO + LND)
└── Second opinion before exenteration
Advantages and Disadvantages of MIS in Gyn Oncology
| Advantages | Disadvantages |
|---|
| Less blood loss | Learning curve |
| Shorter hospital stay | Higher cost (robotic) |
| Faster recovery | Limited tactile feedback |
| Less wound complications | CO2 pneumoperitoneum effects |
| Better visualization (magnification) | Port-site metastasis (rare) |
| Less adhesion formation | LACC trial concern: gas/instrument contamination theory |
Sentinel Lymph Node Biopsy - Summary across Gyn Oncology
| Cancer | Trial | Tracer | Performance |
|---|
| Endometrial | FIRES | ICG (cervical injection) | Sensitivity 97.2% |
| Vulvar | GROINSS-V | Tc99m ± blue dye | NPV >97% (T<4cm) |
| Cervical | SENTICOL | ICG / Tc99m | Sensitivity 90-97% |
| Ovarian | Experimental | - | Not standard |
*Sources: Creasy & Resnik Maternal-Fetal Medicine; Berek & Novak's Gynecology; FIGO 2023-2024 Guidelines; INTERLACE Trial (Lancet 2024); CALLA Trial (Lancet Oncol 2023); KEYNOTE-A18 (Lancet 2024); Braga et al. Clinics 2023 [PMID 37523979]; Wang et al. J Cancer Res Clin Oncol 2023 [PMID 37594534]; LACC Trial (NEJM 2018)*All 10 questions answered. Here's a quick summary of key updates from latest guidelines used:
Key High-Yield Points for This Paper
| Q | Most Important Point |
|---|
| Q1 | NECC in pregnancy: use PE regimen (Cisplatin+Etoposide) NOT standard regimens; CCRT after delivery |
| Q2 | PI3K-AKT-mTOR + PARP pathways are the most actionable in gyn oncology |
| Q3 | WT1 + PAX8 = HGSC; CDX2 + CK20 = GI metastasis (Krukenberg) |
| Q4 | Uterine artery crossing = most common site of ureteric injury (75%); always spatulate + stent |
| Q5 | Prehab = multimodal: exercise + nutrition + psychosocial + anemia Rx; start 3-6 weeks before CRS |
| Q6 | Meijer criteria: ≥90% sensitivity / ≥98% specificity vs HC2; genotyping (16/18) guides triage |
| Q7 | INTERLACE = POSITIVE (carbo+taxol induction before CCRT); CALLA = NEGATIVE (durvalumab failed) |
| Q8 | EMA-CO for high-risk GTN; pembrolizumab for chemo-resistant/refractory GTN |
| Q9 | Gracilis = Type II (medial femoral circumflex); VRAM = Type III (DIEA) - both key for vulvar reconstruction |
| Q10 | LACC Trial: MIS radical hysterectomy is inferior to open - do NOT do MIS radical Hx for cervical cancer |
